Runben Biotechnology Co AAQS
The The AAQS of Runben Biotechnology Co (603193.SS) as of Oct 16, 2026 is 5. In the previous year, The AAQS was 5.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
5
YoY
0.00%
Last updated:
Runben Biotechnology Co has a current AAQS of 5.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Runben Biotechnology Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Runben Biotechnology Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
The Runben Biotechnology Co AAQS history
3 Years
10 Years
25 Years
Max
AAQS
Date
AAQS
Jan 1, 2019
5.00 CNY
Jan 1, 2020
5.00 CNY
Jan 1, 2021
5.00 CNY
Jan 1, 2022
5.00 CNY
Jan 1, 2023
5.00 CNY
Jan 1, 2024
5.00 CNY
Jan 1, 2025
5.00 CNY
| YEAR | AAQS | YoY |
|---|---|---|
| 5 | 0.00% | |
| 5 | 0.00% | |
| 5 | 0.00% | |
| 5 | 0.00% | |
| 5 | 0.00% | |
| 5 | 0.00% | |
| 5 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Runben Biotechnology Co Stock analysis
What does Runben Biotechnology Co do? Runben Biotechnology Co Ltd, trading under the ticker symbol 603193.SS and identified by ISIN CNE100006DK5, is a Chinese enterprise operating within the Consumer Staples sector, specifically in the consumer products industry. Headquartered in Guangzhou, Guangdong, the company has established itself as a specialized manufacturer and distributor of personal care items, with a notable focus on mosquito repellents and baby care solutions. As of the latest available data, the firm employs 917 full-time staff members who support its extensive research, development, manufacturing, and sales operations. Runben Biotechnology officially entered the public markets via an initial public offering on October 17, 2023, marking a significant milestone in its corporate development and providing greater visibility into its financial and operational strategies. The company’s product portfolio is strategically divided into three primary categories: mosquito repellent products, baby care products, and essential oil-based items. Among its best-selling offerings are electric mosquito repellent liquids and DEET-based repellent solutions, which cater to the growing consumer demand for effective and safe pest control measures. In the personal care segment, the firm produces a diverse range of skincare and hygiene products, including lipsticks, face creams, facial cleansers, and general skincare creams, targeting consumers who prioritize gentle and specialized formulations. The company’s business model relies heavily on digital commerce channels, utilizing internet sales platforms to reach its customer base directly. This includes online direct sales, distribution through major online platforms, and agency sales models that facilitate broader market penetration. By leveraging these e-commerce strategies, Runben Biotechnology has been able to maintain a strong presence in the domestic Chinese market, where the majority of its revenue is generated. The firm’s commitment to innovation in product formulation, combined with its agile distribution network, positions it as a competitive player in the crowded consumer goods landscape. Through its continued investment in research and development, the company aims to expand its product lines and enhance the quality of its offerings, ensuring it meets the evolving needs of modern consumers. The integration of traditional manufacturing expertise with modern digital sales tactics allows Runben Biotechnology to adapt quickly to market trends and maintain customer loyalty. As it continues to grow, the company remains focused on delivering high-quality, safe, and effective products that address everyday consumer concerns, particularly in the areas of personal hygiene and family care. Runben Biotechnology Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Runben Biotechnology Co stock
The AAQS of Runben Biotechnology Co is 5 in 2025.
On Eulerpool you can find the complete historical development of The AAQS Runben Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Runben Biotechnology Co
All Key Metrics — Runben Biotechnology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth